Overview of the drug development pipeline for congenital heart disease
Congenital heart disease causes disruption in the blood flow due to the presence of a structural defect in the heart valve, arteries, heart wall, or veins. The congenital heart disease in people can lead to life-threatening conditions such as heart failure. Atrial septal defect and ventricular septal defect are the types of the congenital heart condition. People with this condition suffer from excessive sweating, tiredness and fatigue, fast heartbeat and breathing, clubbed fingernails, and a blue tinge to the skin. Technavio’s market research analysts have predicted that with the introduction of surgery or cardiac catheterization and heart transplantation as some of the most promising approaches to treat congenital heart disease, the global congenital heart disease market will witness growth in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase III drug development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under phase II/III, phase I, and discovery stages.
Congenital heart disease market report: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of congenital heart disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- MEZZION
- Longeveron
- Johnson & Johnson
Therapeutic assessment of the drug development pipeline for congenital heart disease by route of administration
- Oral
- IV
- Intracoronary
The oral route of administration (ROA) involves the administration of drug substances through the mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.
Therapeutic assessment of the drug development pipeline for congenital heart disease by therapeutic modalities
- Small molecule
- Biological
- Gene therapy
According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for congenital heart disease are being developed as small molecules. Small molecules are chemically manufactured active substances that can enter the cells easily due to their low molecular weight of less than 900 Daltons.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Key questions answered in the report include
- What are the drug development molecules in the various development stages of congenital heart disease?
- What are the companies that are currently involved in the development of drug development molecules for congenital heart disease?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.